This week's episode covers common misconceptions about bariatric surgery and other permanent weight loss procedures, with a doctor as guest.
Recap by typeshit. Post by @saladwithasideoffriespod on Instagram.
The plastic surgeon weighs in on semaglutide and other GLP-1 drugs as more patients of every age turn to them for major weight loss.
Toby notes Lilly posted $22.97 billion in Q2 2026 revenue, up 46% in a year, driven by one molecule sold under two brand names.
The actor says GLP-1 drugs can make sense with a doctor's advice, but in his view no drug can stand in for working out.
Keltie Knight shares a personal take on body image pressure on women, tagged with GLP-1 and BookTok. It's a short social clip with few specifics.
The companies shared aging clock data from semaglutide and tirzepatide trials at a conference. Geneticist Steve Horvath called a two year effect strong.
Reports say the Trump administration may let some compounding pharmacies dispense peptides not fully safety tested, and an Auckland academic is concerned.
Loading…